AstraZeneca has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of its president in the country.
The FTSE 100 group has appointed new executives to lead its Chinese oncology business, which has come under intense scrutiny over two incidents including alleged illegal sales practices for cancer drugs.
The scandal ensnared the China president Leon Wang, who the company announced in November had been detained, along with several other employees. AstraZeneca shed more than ￡15bn off its market capitalisation after reports about an investigation by local authorities.
您已閱讀19%（635字），剩余81%（2751字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。